The extensive US budget bill under Senate consideration includes significant changes impacting pharma, including reform proposals for the Inflation Reduction Act’s Medicare drug price negotiation exemptions on orphan drugs. While the bill allows expanded exemptions for orphan drugs treating multiple rare diseases, reforms addressing the 'pill penalty' are absent. Industry groups note impacts on drug development investment, and legislative uncertainty persists amid GOP divides over spending cuts and deficit concerns.